LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) - Dilution Analysis

10-Q filing | 12.4M shares outstanding

10-K filing | 11.6M shares outstanding

8-K filing: Lixte Biotechnology Holdings, Inc. entered into a Share Exchange Agreement with Orbit Capital Inc., exchanging Series C Preferred Stock for common stock and shares of a subsidiary.

10-Q filing | 6.2M shares outstanding

10-Q filing | 4.6M shares outstanding

S-1/A filing: This S-1/A filing relates to the resale of up to 12,626,054 shares of common stock by selling stockholders.

8-K filing: Lixte Biotechnology Holdings, Inc. completed a registered direct offering of 210,675 Common Shares and Pre-Funded Warrants to purchase 763,351 shares of Common Stock at $1.54 per share (or $1.53999 per Pre-Funded Warrant), resulting in gross proceeds of approximately $1,500,000 before deducting fees. ($1.5M proceeds)

8-K filing: Lixte Biotechnology Holdings, Inc. completed a private placement offering of 59,552 Common Shares, 2,322,532 Pre-Funded Warrants, 6,355,214 Common Stock Warrants and 3,573,130 shares of Series B Convertible Preferred Stock, resulting in gross proceeds of approximately $4,000,000 at the initial closing on July 2, 2025.

S-1/A filing: Lixte Biotechnology Holdings, Inc. is offering up to 7,692,308 shares of common stock and pre-funded warrants.

S-1 filing: Lixte Biotechnology Holdings, Inc. is offering 5,263,158 shares of common stock and/or pre-funded warrants to purchase 5,263,158 shares of common stock in a firm commitment public offering, with an underwriter option to purchase up to an additional 789,474 shares of common stock.

8-K filing: Lixte Biotechnology Holdings, Inc. appointed Geordan Pursglove as CEO and Chairman, granting him a stock option for 350,000 shares, and amended Bastiaan van der Baan's employment agreement, fully vesting his existing stock option for 250,000 shares.

8-K filing: Lixte Biotechnology Holdings, Inc. received a notice of conversion for 350,000 shares of Series A Convertible Preferred Stock into 72,917 shares of common stock on May 16, 2025.

10-Q filing | 2.5M shares outstanding

S-1/A filing: This S-1/A filing registers the resale of 467,393 shares of common stock issuable upon exercise of certain warrants by selling stockholders. The company will not receive any proceeds from the sale of these shares, but will receive proceeds from cash exercise of the warrants.

S-1 filing: Lixte Biotechnology Holdings, Inc. is offering 467,393 shares of common stock issuable upon exercise of certain common stock warrants on a resale basis by selling stockholders.

10-K filing | 2.7M shares outstanding

RW filing: Lixte Biotechnology Holdings, Inc. requests the withdrawal of Registration Statement on Form S-1, as amended, File No. 333-282781, and intends to pursue financing needs by utilizing its availability under its effective S-3 registration statement and/or pursuant to a private offering of securities.

10-Q filing | 2.2M shares outstanding

S-1/A filing: Lixte Biotechnology Holdings, Inc. is offering up to 1,895,734 units, each consisting of one share of common stock or one pre-funded warrant and one and one-quarter common warrants at an assumed price of $2.11 per unit, for gross proceeds of up to approximately $4,000,000.

S-1/A filing: Lixte Biotechnology Holdings, Inc. is offering up to 1,895,734 units, each consisting of one share of common stock or one pre-funded warrant and common warrants, for gross proceeds of up to approximately $4,000,000.

S-1 filing: LIXTE Biotechnology Holdings, Inc. is offering units, each consisting of one share of common stock or one pre-funded warrant to purchase one share of common stock and one and one-quarter common warrants to purchase one share of common stock, with WallachBeth Capital LLC acting as the exclusive placement agent.

10-Q filing | 2.2M shares outstanding

8-K filing: Lixte Biotechnology Holdings, Inc. entered into a Consulting Agreement with Dr. Jan H.M. Schellens, who will become the Company's Chief Medical Officer and has been granted stock options to purchase 15,000 shares of the Company's common stock.

10-Q filing | 2.2M shares outstanding

S-3/A filing: Lixte Biotechnology Holdings, Inc. files an S-3/A registration statement for the offer, sale, and issuance of various securities with an aggregate public offering price of up to $50,000,000, and also relates to an aggregate of 583,334 shares of Common Stock for offer and resale by the selling stockholder identified in the Registration Statement issuable by the Company upon exercise of currently outstanding common stock warrants.

S-3 filing: Lixte Biotechnology Holdings, Inc. files an S-3 form to offer and sell up to $50,000,000 of common stock, preferred stock, and debt securities.

10-K filing | 2.2M shares outstanding

10-Q filing | 2.1M shares outstanding

8-K filing: Lixte Biotechnology Holdings, Inc. appointed Bastiaan van der Baan as President and Chief Executive Officer and granted him options to purchase 250,000 shares of the Company's common stock at an exercise price of $1.95 per share.

S-3 filing: The selling stockholder is offering on a resale basis 583,334 shares of common stock issuable upon exercise of certain common stock warrants.

10-Q filing | 2.2M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 16,649,510 → 1,664,951

10-Q filing | 16.6M shares outstanding

10-K filing | 15.8M shares outstanding

8-K filing: The company's Board of Directors authorized the issuance of warrants to BioPharmaWorks LLC to purchase 100,000 shares of common stock at $0.5025 per share, and amended the Bylaws to reduce the quorum for stockholder meetings to 33-1/3%.

10-Q filing | 16.6M shares outstanding

10-Q filing | 16.2M shares outstanding

10-Q filing | 16.6M shares outstanding

10-K filing | 13.7M shares outstanding

10-Q filing | 13.7M shares outstanding

10-Q filing | 13.7M shares outstanding

10-Q filing | 13.5M shares outstanding

10-K filing | 11.2M shares outstanding

S-3 filing: Lixte Biotechnology Holdings, Inc. is offering up to $20,000,000 of any combination of common stock, preferred stock, and debt securities.

8-K filing: On November 30, 2020, the Company completed a public offering of 1,200,000 units, each consisting of one share of common stock and one warrant, at a price of $4.75 per Unit, generating gross proceeds of $5,700,000. ($5.7M proceeds)

8-K filing: Lixte Biotechnology Holdings Inc. executed a 1-for-6 reverse stock split on November 18, 2020, and on November 25, 2020, entered into an underwriting agreement for a public offering of 1,200,000 units at $4.75 per unit, each unit consisting of one share of common stock and one warrant, resulting in gross proceeds of $5.7 million. ($11.4M proceeds)

S-1/A filing: This is an S-1/A filing for Lixte Biotechnology Holdings, Inc. regarding an offering of units, each consisting of one share of common stock and a warrant to purchase one share of common stock.

10-Q filing | 67.0M shares outstanding

S-1/A filing: This is an S-1/A filing providing an update on the company's business, product candidates, clinical trials, and associated risks, including the issuance of warrants to underwriters.

8-K filing: The company entered into a Master Service Agreement with Foundation for Angelman Syndrome Therapeutics, appointed Robert Weingarten as CFO granting him options for 350,000 shares of common stock, and increased Eric Forman's salary and granted him options for 350,000 shares of common stock.

10-Q filing | 67.0M shares outstanding

8-K filing: The company entered into employment agreements with Dr. John Kovach (President, Chief Scientific Officer, and CEO), Eric Forman (Chief Administrative Officer), and Dr. James Miser (Chief Medical Officer), with Dr. Miser receiving options to purchase up to 500,000 shares of the company's common stock.

10-Q filing | 67.0M shares outstanding

10-K filing | 67.0M shares outstanding